Ian Shakil - 03 Apr 2024 Form 4 Insider Report for Augmedix, Inc.

Signature
/s/ Todd Holvick, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
03 Apr 2024
Net transactions value
-$454,454
Form type
4
Filing time
04 Apr 2024, 20:30:04 UTC
Previous filing
03 Apr 2024
Next filing
09 Apr 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AUGX Common Stock Sale $188,600 -45,906 -32% $4.11 95,665 03 Apr 2024 Direct F1
transaction AUGX Common Stock Sale $265,854 -64,055 -67% $4.15 31,610 04 Apr 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades ranging from $4.0800 to $4.2700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.